Asthma is a chronic disease involving airway inflammation, reversible airflow obstruction, and bronchial hyper-responsiveness. The condition is usually triggered by environmental factors of which the symptoms include: difficulty breathing, coughing, wheezing and in some cases a life-threatening asthma attack. Although the condition is not currently curable, the symptoms can be controlled to a more manageable state through stepping up and stepping down treatments according to disease progression.
This report provides the current prevalent population for Asthma across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Asthma have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
The main co-morbidities associated with asthma include:
• Obesity
• Smoking
• COPD
• GERD
• Sleep disorders
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in the global Asthma market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Asthma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Asthma’s prevalent population.
• Identify sub-populations within Asthma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Asthma patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Cachexia
• Features of Asthma Patients
o Asthma by Severity (GINA)
o Asthma by Phenotype (Haldar)
o Asthma by SARP Phenotype
• Refractory (Severe Uncontrolled) Asthma
o Asthma by Atopic Sub-type
o Asthma by EOS + Sub-type
o Asthma by BMI Status
o Asthma by Smoking Status
• Treatment of Asthma with Bronchodilators
• Preventative treatment of Asthma
o Comorbidities in Asthma Patients
• Healthcare Utilisation by patients with Asthma
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• Clinical phenotypes of asthma using cluster analysis
• Stepwise approach to treatment
List of Tables
• GINA Classification parameters
• Prevalence of Asthma, total (000s)
• Prevalence of Asthma, , males (000s)
• Prevalence of Asthma , females (000s)
• Asthma patients by severity, total (000s)
• Asthma patients by Phenotype (Haldar), total (000s)
• Asthma patients by SARP Phenotype, total (000s)
• Prevalence of Refractory (Severe Uncontrolled) Asthma, total (000s)
• Asthma patients by Atopic sub-type, total (000s)
• Asthma patients by EOS + sub-type, total (000s)
• Asthma patients by BMI status, total (000s)
• Asthma patients by smoking status, total (000s)
• Treatment of asthma with quick-acting bronchodilators, total (000s)
• Treatment of asthma with quick-acting bronchodilators by asthma severity (000s)
• Patients with Asthma receiving preventative treatment, total (000s)
• Patients receiving preventative treatment by asthma severity (000s)
• Prevalence of GERD in Patients with Moderate & Severe Asthma, total (000s)
• Prevalence of Diabetes in Patients with Moderate & Severe Asthma, total (000s)
• Prevalence of COPD in asthma patients, total (000s)
• Prevalence of Atopic Dermatitis in asthma patients, total (000s)
• Hospitalised overnight due to asthma in past 12 months, total (000s)
• Visited ER due to asthma in past 12 months, total (000s)
• Unscheduled medical visit due to asthma in past 12 months, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Asthma by 5-yr age cohort, males (000s)
• USA Prevalence of Asthma by 5-yr age cohort, females (000s)
• France Prevalence of Asthma by 5-yr age cohort, males (000s)
• France Prevalence of Asthma by 5-yr age cohort, females (000s)
• Germany Prevalence of Asthma by 5-yr age cohort, males (000s)
• Germany Prevalence of Asthma by 5-yr age cohort, females (000s)
• Italy Prevalence of Asthma by 5-yr age cohort, males (000s)
• Italy Prevalence of Asthma by 5-yr age cohort, females (000s)
• Spain Prevalence of Asthma by 5-yr age cohort, males (000s)
• Spain Prevalence of Asthma by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of Asthma by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of Asthma by 5-yr age cohort, females (000s)
• Brazil Prevalence of Asthma by 5-yr age cohort, males (000s)
• Brazil Prevalence of Asthma by 5-yr age cohort, females (000s)
• Japan Prevalence of Asthma by 5-yr age cohort, males (000s)
• Japan Prevalence of Asthma by 5-yr age cohort, females (000s)
